-+ 0.00%
-+ 0.00%
-+ 0.00%

Nanobiotix says Phase 2 CONVERGE study shows 85.7% response rate for JNJ-1900 in Stage 3 inoperable NSCLC

PUBT·06/02/2026 20:32:18
Listen to the news
Nanobiotix says Phase 2 CONVERGE study shows 85.7% response rate for JNJ-1900 in Stage 3 inoperable NSCLC
  • Nanobiotix highlighted updated Phase 2 CONVERGE results for JNJ-1900 (NBTXR3) in inoperable stage 3 NSCLC, already presented at ESTRO 2026.
  • Investigators reported strong tumor shrinkage signals, including deep responses, with no disease worsening seen in the small treated cohort.
  • Safety looked acceptable, with no serious treatment-related events reported, supporting feasibility of intratumoral or intranodal delivery.
  • The FDA accepted a NANORAY-312 Phase 3 protocol change in head and neck cancer, removing the interim readout to bring the final analysis forward.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanobiotix SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606021630OMX_____CNEWS_EN_GNW9730796_en) on June 02, 2026, and is solely responsible for the information contained therein.